Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.35
- Piotroski Score 1.00
- Grade N/A
- Symbol (RENB)
- Company Renovaro Biosciences Inc.
- Price $0.48
- Changes Percentage (-3.65%)
- Change -$0.02
- Day Low $0.46
- Day High $0.50
- Year High $5.25
Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 09/29/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.80
- Trailing P/E Ratio -1.61
- Forward P/E Ratio -1.61
- P/E Growth -1.61
- Net Income $-39,684,056
Income Statement
Quarterly
Annual
Latest News of RENB
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The week in classical: Prom 31: West-Eastern Divan Orchestra/Barenboim; GBSR Duo - review
Renowned musician Daniel Barenboim led an emotional concert with his ensemble at the Royal Albert Hall, showcasing his enduring musical prowess despite frail health. The performance was a poignant tes...
By The Guardian | 1 month ago -
Prom 31: West-Eastern Divan Orchestra/Barenboim review - an unforgettable and heroic return
After a two-year absence due to a serious neurological condition, conductor Daniel Barenboim returned to the Royal Albert Hall in London with his West-Eastern Divan Orchestra. Despite his frailty, he ...
By The Guardian | 1 month ago -
Level of Ural River in Russia's Orenburg reaches 11.83 metres, say local authorities
MOSCOW (Reuters) - The level of the Ural river in the Russian city of Orenburg has reached 11.83 metres, or around 39 feet, local authorities said on Saturday, after major rivers burst their banks...
By Reuters | 5 months ago
